Oncolytic immunotherapy

This page covers all Oncolytic immunotherapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Tumor cells (non-selective replication); immunostimulatory transgene product, IL-12 expression; adenovirus replication machinery.

Targets

Tumor cells (non-selective replication); immunostimulatory transgene product · IL-12 expression; adenovirus replication machinery

Marketed (1)

• Zopapogene imadenovec (Zopa) · Precigen, Inc · Oncology
  Zopapogene imadenovec is an oncolytic adenovirus engineered to express an immunostimulatory transgene that replicates in tumor cells and triggers anti-tumor immune responses.

Phase 3 pipeline (1)

• aglatimagene besadenovec + valacyclovir · Candel Therapeutics, Inc. · Oncology
  Aglatimagene besadenovec is an oncolytic adenovirus expressing IL-12 that replicates in tumor cells and triggers immune activation, combined with valacyclovir (an antiviral) to modulate viral replication kinetics.